Who are CDCA Weight-Based Dose TID's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oral chenodeoxycholic acid stimulation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cdca-weight-based-dose-tid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CDCA Weight-Based Dose TID — Competitive Intelligence Brief

CDCA Weight-Based Dose TID (CDCA Weight-Based Dose TID) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bile acid receptor agonist. Area: Hepatology / Gastroenterology.

phase 3 Bile acid receptor agonist FXR (farnesoid X receptor), TGR5 Hepatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

CDCA Weight-Based Dose TID (CDCA Weight-Based Dose TID) — Mirum Pharmaceuticals, Inc.. CDCA (chenodeoxycholic acid) is a bile acid that activates farnesoid X receptor (FXR) and TGR5 signaling to reduce bile acid synthesis and improve cholestasis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CDCA Weight-Based Dose TID TARGET	CDCA Weight-Based Dose TID	Mirum Pharmaceuticals, Inc.	phase 3	Bile acid receptor agonist	FXR (farnesoid X receptor), TGR5
Oral chenodeoxycholic acid stimulation	Oral chenodeoxycholic acid stimulation	Lars Kristian Munck	marketed	Bile acid receptor agonist	FXR (farnesoid X receptor), TGR5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bile acid receptor agonist class)

Lars Kristian Munck · 1 drug in this class
Mirum Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CDCA Weight-Based Dose TID — Competitive Intelligence Brief. https://druglandscape.com/ci/cdca-weight-based-dose-tid. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab